CO2024009774A2 - Composiciones que contienen fexofenadina - Google Patents

Composiciones que contienen fexofenadina

Info

Publication number
CO2024009774A2
CO2024009774A2 CONC2024/0009774A CO2024009774A CO2024009774A2 CO 2024009774 A2 CO2024009774 A2 CO 2024009774A2 CO 2024009774 A CO2024009774 A CO 2024009774A CO 2024009774 A2 CO2024009774 A2 CO 2024009774A2
Authority
CO
Colombia
Prior art keywords
fexofenadine
spray dried
zwitterion
dihydrate
dried formulation
Prior art date
Application number
CONC2024/0009774A
Other languages
English (en)
Spanish (es)
Inventor
Daniela Maldonado Cavalari
Maxime Liboureau
Chakib Zaghloul
Original Assignee
Opella Healthcare Group Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opella Healthcare Group Sas filed Critical Opella Healthcare Group Sas
Publication of CO2024009774A2 publication Critical patent/CO2024009774A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2024/0009774A 2021-12-29 2024-07-23 Composiciones que contienen fexofenadina CO2024009774A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/000916 WO2023126637A1 (en) 2021-12-29 2021-12-29 Compositions containing fexofenadine

Publications (1)

Publication Number Publication Date
CO2024009774A2 true CO2024009774A2 (es) 2024-08-08

Family

ID=80122351

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0009774A CO2024009774A2 (es) 2021-12-29 2024-07-23 Composiciones que contienen fexofenadina

Country Status (13)

Country Link
US (1) US20250082623A1 (cg-RX-API-DMAC10.html)
EP (1) EP4456880B1 (cg-RX-API-DMAC10.html)
JP (1) JP7826492B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240136358A (cg-RX-API-DMAC10.html)
CN (1) CN118715004A (cg-RX-API-DMAC10.html)
AR (1) AR128113A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021480621A1 (cg-RX-API-DMAC10.html)
CA (1) CA3242293A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024009774A2 (cg-RX-API-DMAC10.html)
ES (1) ES3069308T3 (cg-RX-API-DMAC10.html)
MX (1) MX2024008242A (cg-RX-API-DMAC10.html)
PE (1) PE20242355A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023126637A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
CN102512389B (zh) 2011-12-27 2013-08-21 天津市嵩锐医药科技有限公司 非索非那定盐酸盐口腔崩解药物组合物
KR101761983B1 (ko) * 2014-08-25 2017-08-07 아주대학교산학협력단 구강내 속붕해 필름 조성물 및 그 제조방법
CN105997910A (zh) 2016-06-09 2016-10-12 北京化工大学 一种掩味制剂及其制备方法

Also Published As

Publication number Publication date
US20250082623A1 (en) 2025-03-13
AU2021480621A1 (en) 2024-07-18
EP4456880A1 (en) 2024-11-06
ES3069308T3 (en) 2026-06-05
PE20242355A1 (es) 2024-12-16
MX2024008242A (es) 2024-07-19
EP4456880B1 (en) 2026-03-18
JP7826492B2 (ja) 2026-03-09
KR20240136358A (ko) 2024-09-13
JP2024546513A (ja) 2024-12-24
AR128113A1 (es) 2024-03-27
EP4456880C0 (en) 2026-03-18
CA3242293A1 (en) 2023-07-06
WO2023126637A1 (en) 2023-07-06
CN118715004A (zh) 2024-09-27

Similar Documents

Publication Publication Date Title
AR080912A1 (es) Formas de dosificacion solidas orales con dosis muy bajas para la hrt
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
HK1247822A1 (zh) 用於活性剂口服给药的制剂
ECSP11011456A (es) Inhibidores de la replicación viral novedosos
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
CO6321221A2 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
CR20120062A (es) Terapia combinada para el tratamiento de la diabetes
CL2017001913A1 (es) Composición tópica curativa
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022005503A (es) Composiciones farmaceuticas de apixaban de desintegracion oral.
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
UY40282A (es) Compuestos amido-heteroaromáticos
MX2015013934A (es) Pastilla para tratar garganta irritada, ronquera y tos seca asociada, y enfermedades inflamatorias de la cavidad oral y faringea.
CO2025007025A2 (es) Formulaciones orales compactables de ibutamoren
MX2024008242A (es) Composiciones que contienen fexofenadina.
BR112022020897A2 (pt) Forma de dosagem oral sólida compreendendo pomalidomida.
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
AR091984A1 (es) Composicion oral solida que contiene colorantes para uso en diagnostico endoscopico
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
CO2026005974A2 (es) Un péptido cíclico para atrapar la interleucina-1 beta
BR112015028581A2 (pt) composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica